Drugs / Imipenem/Cilastatin/Relebactam
Imipenem/Cilastatin/Relebactam
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05146154 | Jan → Jun 2023 | critical illness polyneuropathy, obesity disorder | University of Illinois at Chicago | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-04-22 | Merck Sharp & Dohme LLC | Results Pivotal Phase 3 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Demonstrated Favorable Overall Response Against Certain Imipenem–Non-Susceptible Bacterial Infections merck.com ↗
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a pivotal Phase 3 study of relebactam, the company’s investigational beta-lactamase inhibitor, in combination with imipenem/cilastatin, demonstrated a favorable overall response in the treatment of certain imipenem–non-susceptible bacterial infections, the primary endpoint, with lower treatment-emergent nephrotoxicity (kidney toxicity), a secondary endpoint, compared to a Colistin (colistimethate sodium) plus imipenem regimen. |
| 2015-09-18 | Merck Sharp & Dohme LLC | Results Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015 merck.com ↗
In the Phase 2 study, relebactam in combination with imipenem/cilastatin demonstrated noninferiority in the percentage of microbiologically evaluable patients with favorable clinical response at the end of intravenous therapy compared to imipenem/cilastatin alone. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-04-22 | Merck Sharp & Dohme LLC | Pivotal Phase 3 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Demonstrated Favorable Overall Response Against Certain Imipenem–Non-Susceptible Bacterial Infections merck.com ↗ |
| 2015-09-18 | Merck Sharp & Dohme LLC | Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015 merck.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imipenem/Cilastatin/Relebactam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05146154 ↗ |
| Action | Inhibit | “beta-lactamase inhibitor” NCT05146154 ↗ |
| Modality | Other / unclassified | “combination beta-lactam/beta-lactamase inhibitor antimicrobial” NCT05146154 ↗ |